All In MedTech

Device Trial Radar · NCT06199635

Early Feasibility for Safety & Device Functionality of SFM Anastomosis Device Used in 3 Procedures (SNAP-S) or (SNAP-PS) or (J-J)

Evaluate the Initial Safety and Device Functionality of the SFM Anastomosis Device for a Primary Sleeve Gastrectomy Duodenal-Ileal Anastomosis (SNAP-S) or After Primary Sleeve Gastrectomy (SNAP-PS) or to Create a Jejuno-Jejunostomy in a Roux-en-Y Gastric Bypass (J-J)

Last checked: Nov 19, 2026Latest source record: Jul 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

28

Actual

Start

Dec 15, 2023

Primary completion

Jan 15, 2025

Study completion Jul 8, 2026

Sponsor

Lead sponsor
GI Windows, Inc.Not on our public-company list
Sponsor type
Industry
First posted
Jan 10, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objectives of this study are to assess the initial safety and device functionality of the SFM Anastomosis System including delivery systems when used to create a duodenal-ileal (D-I) anastomosis either during sleeve gastrectomy (i.e., SNAP-S procedure) or patients with prior sleeve gastrectomy who experience inadequate weight loss (i.e., SNAP-PS procedure) or a Roux-en-Y gastric bypass jejuno-jejunostomy. Additionally, the study is designed to evaluate the potential of these procedures to induce weight loss and to improve metabolic comorbidities in obese subjects.

Conditions

  • Morbid Obesity

Interventions

  • Self-Forming Magnetic Anastomosis Device and Delivery SystemDevice

    Self-Forming Magnetic Anastomosis Device to create a gastrointestinal anastomosis

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Effectiveness Endpoint:Time frame: 30 days
  2. Primary Safety Endpoint:Time frame: 30 days

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Clinica Colonial Hospital

    Santiago, Huechuraba, Región Metropolitana, Chile

  • Bhandari Hospital & Research Centre

    Indore, Madhya Pradesh, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.